- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/095 - Rhinovirus
Détention brevets de la classe C07K 14/095
Brevets de cette classe: 17
Historique des publications depuis 10 ans
|
1
|
1
|
1
|
0
|
1
|
0
|
3
|
1
|
0
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1600 |
2 |
| Beijing Children's Hospital Affiliated to Capital Medical University | 3 |
2 |
| Biological Mimetics, Inc. | 25 |
2 |
| bioMerieux | 910 |
2 |
| Institute of Pathogen Biology, Chinese Academy of Medical Sciences | 13 |
2 |
| Ip2ipo Innovations Limited | 173 |
2 |
| President and Fellows of Harvard College | 6118 |
1 |
| The University of Birmingham | 429 |
1 |
| Sanofi | 4342 |
1 |
| Boehringer Ingelheim Animal Health USA Inc. | 415 |
1 |
| Biortus Discovery Co., Ltd | 6 |
1 |
| Autres propriétaires | 0 |